You are now visiting tipharma.com.
On 1 January, 2016, TI Pharma and CTMM merged
to form a new organization called Lygature.
Please note that information on the tipharma.com site has not
been updated since, and is retained as an archive.
For up-to-date information, please visit lygature.org.
Escher: science-driven drug regulation
The pharmaceutical arena is one of the most regulated sectors in our society. However, there is increasing concern that, apart from all the benefits of drug regulation, the balance sheet may have shifted towards over-regulation with apparent threats to drug innovation in general.
A major goal of regulating marketing authorization of medicines is to secure safe and effective drugs, but such regulations are also driving high costs of drug development; regulations affecting reimbursement and access to the market are key to cost-containment but may also provide major barriers for investors and industry to stimulate innovation.
Key objectives of this project are to identify, evaluate and remove regulatory bottlenecks hampering the efficiency in pharmaceutical innovation and stimulate factors helping innovation . The project encompasses three synergistic areas of research directed at regulatory barriers and opportunities in drug innovation, innovative models of testing, and monitoring efficacy and safety of new drugs and knowledge management, learning and education. A major achievement has been the agenda-setting function of the project towards stakeholders and politicians.
For more information please visit: www.escher-projects.org
Full project title: The Escher project: science-driven drug regulation and innovative research throughout phased drug development
Start date: July 2007
End date: July 2012
Goal: Create a better insight and grip on the regulation of drugs
Principal investigator: Bert Leufkens
Project size: 19 FTE's
Partners: Amgen, Erasmus Medical Center, GlaxoSmithKline, Schering-Plough, Merck & Co., University Medical Center Groningen, University Medical Center Utrecht, University Utrecht, WINap
Various analyses (Rawlins Nat Drug Discovery 2004, FDA Critical Path, EMEA Roadmap, EU Innovative Medicines Initiative, WHO Priority Medicines) have provided evidence that the current system of pharmaceutical innovation is not sustainable anymore, both from a economic point of view and from the perspective of unmet medical needs, therapeutic gaps and access to medicines. At the same time, lack of efficacy (25%) and clinical safety (12%) are still major reasons for drug development projects to be stopped prematurely. Insufficient predictive capability, complexities in essay sensitivity, lack of validated and accepted biomarkers are important hampering factors across virtually all the discovery, pre-clinical and clinical phases of drug development.
Frederieke van der Baan (project T6-202)
Personalized Medicine: Pharmacogenetic Testing in Drug Development and Clinical Practice
Yan Miao (project T6-202)
Off-target effects of RAAS-inhibition:importance on renal outcomes in patients with diabetes
Jacoline Bouvy (project T6-202)
The evaluation of drug regulation - Economic approaches into the valuation and evaluation of the drug regulatory framework
Michelle Putzeist (project T6-202)
Marketing authorisation of new medicines in the EU: towards evidence-based improvement
“What TI Pharma can deliver from collaborations is more efficient healthcare, faster time to market and quicker patient benefit.”